Contract Research Giant IQVIA's Data Assets Are Biggest Differentiator, Provides Best Exposure To AI And Data Opportunities: Analyst
Contract Research Giant IQVIA's Data Assets Are Biggest Differentiator, Provides Best Exposure To AI And Data Opportunities: Analyst
As a result, the stock has underperformed the S&P 500 by about 26% since Q1 2022.RBC Capital Markets initiated coverage on IQVIA Holdings Inc. (NYSE:IQV), noting the company's biggest differentiator is its data assets. The analyst says IQVIA is the largest global contract research organization.
RBC資本市場對IQVIA Holdings Inc. (NYSE:IQV)啓動了覆蓋，指出該公司最大的區別在於其數據資產。分析師表示IQVIA是全球最大的合同研究組織。
The analyst notes investor sentiment and EPS growth have been significantly impacted over the past 2.5 years due to persistent challenges from the COVID-19 pandemic, rising interest expenses, a declining biopharma funding environment, and weaker discretionary and commercial demand.
分析師指出，過去2.5年來，投資者情緒和每股收益增長受到了嚴重影響，原因是持續挑戰來自COVID-19大流行、不斷上升的利息開支、日益下滑的生物製藥資金環境，以及較弱的自由裁量和商業需求。
Also Read: IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings.
另請參閱：分析師表示IQVIA在Q2業績超預期後'是一個穩固的投資'，擁有強大的競爭優勢。
As a result, the stock has underperformed the S&P 500 by about 26% since Q1 2022.
因此，自2022年第一季度以來，該股票的表現比S&P 500指數下跌了約26%。
RBC writes that IQVIA offers the best exposure to the vast AI and data opportunities in drug development, boasting one of the largest healthcare data collections in the industry.
RBC表示IQVIA在藥物開發領域提供了最廣闊的人工智能和數據機遇，擁有行業中最大的醫療數據收集之一。
The company manages over 61 petabytes of data and 1.2 billion patient records from more than 150,000 data suppliers.
該公司管理超過61PB的數據和來自150,000多個數據供應商的12億患者記錄。
IQV estimates that in 2023, biopharma companies spent around $50 billion on outsourced clinical drug development that could have been addressed by IQVIA's solutions, representing a 17% market penetration compared to their $8.4 billion R&D revenue for the year.
IQV估計在2023年，生物製藥公司在外包臨床藥物開發方面的支出約爲500億美元，而這些支出本可以通過IQVIA的解決方案解決，佔據了17%的市場份額，相比其在該年的84億美元的研發營收。
IQV also suggests another $150 billion in spending across other business areas, indicating a 4–5% market penetration in these segments.
IQV還提出在其他業務領域的升級支出約1500億美元，表明在這些領域有4-5%的市場滲透率。
RBC initiates with an Outperform rating with a price target of $275. Looking ahead, RBC Capital notes that four macro analyses/models indicate that the fading headwinds will lead to a significant rebound in EPS growth, which will likely push IQVIA's valuation back toward its historical average.
野村證券給予IQUIA超越市場表現的評級，並設定目標價格爲275美元。展望未來，野村資本指出，四個宏觀分析/模型顯示，消退的逆風將導致EPS增長的顯著反彈，這可能將推動IQUIA的估值回到其歷史平均水平。
- Biotech Funding: Significant acceleration in Q1, which is a longer-term indicator and also influences EBP, now comprising ~25% of R&D bookings.
- Industry R&D: The analyst model shows upward momentum into 2025, a shorter-term indicator.
- Clinical Trials: Phase 3/4 trials have increased in 2024, reflecting current trends.
- FDA Approvals: There has been a notable rise in FDA NME/BLA approvals in 2023.
- 生物技術融資：一季度加速顯著，這是一箇中長期指標，也影響EBP，現在佔研發預訂的25%左右。
- 行業研發：分析師模型顯示到2025年的上行動量，這是一個短期指標。
- 臨床試驗：2024年3/4期試驗增加，反映了當前的趨勢。
- FDA批准：2023年FDA新藥/生物類似物產品批准有顯著增長。
Price Action: IQV stock was down 0.49% to $247.59 at the last check on Wednesday.
價格走勢：上次週三查看時，IQUIA股價下跌0.49%，至247.59美元。
- CrowdStrike Faces Short-Term Challenges Like Pipeline Delays, Deal Scrutiny, and Discounting Pressure, Analyst Says.
- 分析師稱，CrowdStrike面臨短期挑戰，如管道延誤、交易審核和折扣壓力。
譯文內容由第三人軟體翻譯。
